| Name | Title | Contact Details |
|---|
InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany as well as Ann Arbor, Michigan. InflaRx is listed on the Nasdaq Global Select Market in the United States under the trading symbol “IFRX”.
Clearside Biomedical, Inc. is a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic, blinding diseases of the eye.
Galderma Canada Inc. is a Thornhill, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Paragon 28 was established for unmet needs of the foot and ankle community. Dedicated to creating solutions to improve the treatment of foot and ankle conditions.
fusionmed is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.